NHS England reconsiders 'hub and spoke' dispensing model as part of its long-term plan
Hub and spoke dispensing could be revisited following publication of the new NHS ten-year plan.
Source: Suzanne Elvidge
NHS England is again considering changes to government regulations around ‘hub and spoke’ dispensing as part of its ten-year plan.
The ‘’, published on 7 January 2018, discussed “exploring further efficiencies through reform of reimbursement and wider supply arrangements”.
NHS England told Jizak that these efficiencies refer to efficiency of dispensing by using new technology and automation, as the pharmacy “sector continues to flag shortcomings in the operation of the reimbursement system”.
It added that improving dispensing efficiencies may require changes to government regulations around hub and spoke dispensing.
The hub and spoke dispensing model is currently permitted under legislation within the same pharmacy business, but in 2016 the Department of Health and Social Care consulted on changing regulations to allow it across different entities.
The consultation, , suggested allowing “independent pharmacists to make use of ‘hub and spoke’ dispensing models — a ‘hub’ pharmacy dispenses medicines on a large scale, often by making use of automation, preparing and assembling the medicines for regular ‘spoke’ pharmacies that supply the medicines to the patient”.
However, the proposals raised several questions with pharmaceutical representative bodies, including on whether the model was safe and how it would comply with the Falsified Medicines Directive. As a result, the government shelved plans in June 2016 to implement the model.
In its , the Pharmaceutical Services Negotiating Committee (PSNC) said any move to alter hub and spoke dispensing models raised both concerns and opportunities.
The report said: “The PSNC considered whether there might be greater benefits from automated dispensing/hub and spoke dispensing that can be realised under revised legislation. There was consensus that community pharmacy needs to lead the development of any changes and that PSNC must have conversations with government about hub and spoke dispensing and technology.”
The report expressed “concerns about what hub and spoke dispensing would mean for professional liability” as well as outstanding questions over “the spoke’s costs for using a hub and how we would deal with margin and payments/fees”.
Lee Dentith, chief executive of Now Healthcare Group, which provides a smartphone app that allows patients to order repeat prescriptions, told Jizak that plans “to adapt the present pharmacy model to increase the ‘efficiency’ of dispensing, cannot come soon enough”.
While he said it was “too early” to comment on how a hub and spoke system would impact its business model, he added that the online pharmacy company — which dispenses around 20,000 prescriptions per month — “could evolve and become a ‘hub’ for community pharmacies, bridging a gap and meeting the aims set out by the NHS to free-up time for community pharmacists to spend with patients”.
Citation: Jizak DOI: 10.1211/PJ.2019.20205985
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00
Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.£33.00
Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.£33.00
A practical and succinct overview of the principal pharmacy practice topics, for new pharmacy students.£33.00
Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.£40.00